|
gptkbp:instanceOf
|
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvedBy
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
1983
|
|
gptkbp:ATCCode
|
gptkb:N06AB08
|
|
gptkbp:brand
|
gptkb:Luvox
gptkb:Faverin
gptkb:Floxyfral
|
|
gptkbp:CASNumber
|
61718-82-9
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicines
|
|
gptkbp:contraindication
|
concomitant use with MAO inhibitors
hypersensitivity to fluvoxamine
|
|
gptkbp:discoveredBy
|
gptkb:Solvay_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
15-26 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C15H21F3N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluvoxamine
|
|
gptkbp:interactsWith
|
gptkb:tricyclic_antidepressants
gptkb:phenytoin
gptkb:theophylline
gptkb:warfarin
gptkb:SSRIs
gptkb:benzodiazepines
gptkb:carbamazepine
gptkb:clozapine
gptkb:SNRIs
gptkb:St._John's_Wort
caffeine
lithium
antipsychotics
anticonvulsants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits serotonin reuptake
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
80%
|
|
gptkbp:PubChem_CID
|
5327
DB00176
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
sweating
insomnia
dry mouth
gastrointestinal disturbance
sexual dysfunction
somnolence
|
|
gptkbp:UNII
|
O4L1XPO44W
|
|
gptkbp:usedFor
|
gptkb:COVID-19_(investigational)
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
gptkb:bulimia_nervosa
gptkb:autism_spectrum_disorder_(off-label)
gptkb:body_dysmorphic_disorder
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:CYP1A2
|
|
gptkbp:bfsLayer
|
5
|